ING Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

ING Group’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-38,600	Closed	-$467K	–	791
2019 Q2	$467K	Buy	+38,600	New	+$210K	0.01%	534

Other funds holding PRVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

ING Group's PRVB Position: Q3 2019 in Review

ING Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2019, closing a stake of 38,600 shares — an estimated $467K sold.

ING Group first reported a position in PRVB in Q2 2019 and held it in 1 quarter. The position peaked at $467K in Q2 2019. 48 funds tracked by Wall St. Rank hold PRVB as of Q3 2019.

ING Group reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
ING Group sold 38,600 Provention Bio, Inc. Common Stock shares in Q3 2019, an estimated $467K.
ING Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
ING Group's Provention Bio, Inc. Common Stock position peaked at $467K in Q2 2019.
48 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.